NCT04116164 2023-09-25Safety and Targeting of Anti-hk2 Antibody in mCRPCSpectronRXPhase EARLY_PHASE1 Terminated27 enrolled
NCT04674488 2020-12-19TILs for Treatment of Metastatic or Recurrent Cervical CancerShanghai OriginCell Therapeutics Co., Ltd.Phase EARLY_PHASE1 Unknown15 enrolled